Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLI5100 in gastroesophageal reflux disease
NCT05890001Phase 3Completed
- Sponsor
- Braintree Laboratories
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Braintree Laboratories. Primary endpoint: Treatment-Emergent Adverse Events at 31 weeks. Started Apr 2023; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05890001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890001.